Antipsychotic drug use in pregnancy: High dimensional, propensity matched, population based cohort study

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Vigod, Simone N ^a,b   Gomes, Tara ^b   Wilton, Andrew S ^b   Taylor, Valerie H ^a   Ray, Joel G ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADAPTATION SYNDROME; ADULT; ARTICLE; BRAIN HEMORRHAGE; CESAREAN SECTION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FETAL WELL BEING; HOSPITAL READMISSION; HUMAN; INFANT; INFANTILE SPASM; LABOR INDUCTION; LARGE FOR GESTATIONAL AGE; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PERINATAL DRUG EXPOSURE; POPULATION BASED CASE CONTROL STUDY; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROPENSITY SCORE; SEPSIS; SMALL FOR DATE INFANT; SOLUTIO PLACENTAE; VAGINAL DELIVERY; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; COHORT ANALYSIS; EVALUATION STUDY; FACTUAL DATABASE; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; NEWBORN; POISSON DISTRIBUTION; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; MATCHED-PAIR ANALYSIS; POISSON DISTRIBUTION; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; PROPENSITY SCORE; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84930674696     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h2298     Document Type: Article

References (43)

1. Toh S, Li Q, Cheetham TC, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the US, 2001-2007: a population-based study of 585, 615 deliveries. Arch Womens Ment Health 2013;16:149-57.
2. Vigod SN, Seeman MV, Ray JG, et al. Temporal trends in general and age-specific fertility rates among women with schizophrenia (1996-2009): a population-based study in Ontario, Canada. Schizophr Res 2012;139:169-75.
3. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44.
4. Kennedy SH, Lam RW, Parikh SV, etal. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord 2009;117(suppl 1):S1-2.
5. Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007;164:1817-24; quiz 923.
6. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010;36:518-44.
7. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(suppl 4):8-13.
8. Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Safety 2014;37:79-90.
9. Abel KM. Fetal antipsychotic exposure in a changing landscape: seeing the future. Br J Psychiatry 2013;202:321-3.
10. Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA 2005;294:2751-7.
11. Levy AR, Obrien BJ, Sellors C, et al. Coding accuracy of administrative drug claims in the Ontario drug benefit database. Can J Clin Pharmacol 2003;10:67-71.
12. Juurlink DPC, Croxford R, Chong A, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Toronto, 2006.
13. Hirdes JP, Smith TF, Rabinowitz T, et al. The Resident Assessment Instrument-Mental Health (RAI-MH): inter-rater reliability and convergent validity. J Behav Health Serv Res 2002;29:419-32.
14. Urbanoski KA, Mulsant BH, Willett P, et al. Real-world evaluation of the Resident Assessment Instrument-Mental Health assessment system. Can J Psychiatry 2012;57:687-95.
15. Hux JE, Ivis F, Flintoft V, et al. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512-6.
16. Quan H, Khan N, Hemmelgarn BR, et al. Validation of a case definition to define hypertension using administrative data. Hypertension 2009;54:1423-8.
17. Parkerson GR Jr, Harrell FE Jr, Hammond WE, et al. Characteristics of adult primary care patients as predictors of future health services charges. Med Care 2001;39:1170-81.
18. You JJ, Alter DA, Stukel TA, et al. Proliferation of prenatal ultrasonography. CMAJ 2010;182:143-51.
19. Ray JG, Schull MJ, Urquia ML, et al. Major radiodiagnostic imaging in pregnancy and the risk of childhood malignancy: a population-based cohort study in Ontario. PLoS Med 2010;7:e1000337.
20. Gomes T, Juurlink DN, Ho JM, et al. Risk of serious falls associated with oxybutynin and tolterodine: a population based study. J Urol 2011;186:1340-4.
21. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512-22.
22. Rassen JA, Glynn RJ, Brookhart MA, et al. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 2011;173:1404-13.
23. Ros H. Preeclampsia and other circulatory diseases during pregnancy-etiological aspects and impact on female offspring. Karolinska University Press, 2001.
24. Joseph KS, Fahey J. Validation of perinatal data in the Discharge Abstract Database of the Canadian Institute for Health Information. Chronic Dis Can 2009;29:96-100.
25. Joseph KS, Liu S, Rouleau J, et al. Severe maternal morbidity in Canada, 2003 to 2007: surveillance using routine hospitalization data and ICD-10CA codes. J Obstet Gynaecol Can 2010;32:837-46.
26. Ray JG, Sgro M, Mamdani MM, et al. Birth weight curves tailored to maternal world region. J Obstet Gynaecol Can 2012;34:159-71.
27. Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352:2477-86.
28. Ray JG, Vermeulen MJ, Shapiro JL, et al. Maternal and neonatal outcomes in pregestational and gestational diabetes mellitus, and the influence of maternal obesity and weight gain: the DEPOSIT study. Diabetes Endocrine Pregnancy Outcome Study in Toronto. QJM 2001;94:347-56.
29. Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009;361:1339-48.
30. Landon MB, Mele L, Spong CY, et al. The relationship between maternal glycemia and perinatal outcome. Obstet Gynecol 2011;117:218-24.
31. Urquia ML, Frank JW, Glazier RH, et al. Birth outcomes by neighbourhood income and recent immigration in Toronto. Health Reports 2007;18:21-30.
32. Canadian Perinatal Surveillance System. Perinatal health indicators for Canada: a resource manual. Ottawa, 2000.
33. Public Health Agency of Canada. Canadian Perinatal Health Report, 2008 Edition. Ottawa, Ontario, Canada, 2008.
34. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013;70:436-43.
35. Boden R, Lundgren M, Brandt L, et al. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ 2012;345:e7085.
36. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9.
37. Bellantuono C, Tofani S, Di Sciascio G, et al. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry 2013;35:3-8.
38. Quispel C, Bangma M, Kazemier BM, et al. The role of depressive symptoms in the pathway of demographic and psychosocial risks to preterm birth and small for gestational age. Midwifery 2014;30:919-25.
39. Borders AE, Grobman WA, Amsden LB, et al. Chronic stress and low birth weight neonates in a low-income population of women. Obstet Gynecol 2007;109:331-8.
40. Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28:279-88.
41. Boden R, Lundgren M, Brandt L, et al. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry 2012;69:715-21.
42. National Diabetes Surveillance System. Diabetes in Canada. Canada, 2008.
43. Canadian Chronic Disease Surveillance System. Hypertension in Canada, 2010.